In this community, professionals share information regarding the clinical, programmatic and community-oriented aspects of early diagnosis, treatment and prevention of multi-drug-resistant tuberculosis (MDR-TB). Members also use this forum to promote universal access to quality care for MDR-TB.

Community moderators

Masoud Dara, MD
WHO Europe - EURO
Christopher Gilpin, PhD, MPH
World Health Organization - WHO
Dylan Tierney
Brigham and Women's Hospital, Division of Global Health Equity

Current Expert Panels

Tuberculosis Among Migrants

This Expert Panel will examine evidence-based and rights-based interventions and advocacy to prevent, diagnose, and treat TB in migrants.

Jan. 16, 2017 - Jan. 20, 2017

Join this panel

Recent community activity

Access to New TB medicines: Time to Enhance Our Support to Pharmacovigilance Systems

by Syed Rizwanuddin Ahmad

Dear All, A study published in a major journal again identified lack of development of systems for pharmacovigilance as barriers to access to bedaquiline. The authors emphasized that despite limitations increased access to bedaquiline is possible with the presence of clinical review committee; easy access to ECG monitoring; and presence ... read more

Updated: 19 Jan, 2017
Replies: 0

Outcomes, infectiousness, and transmission dynamics of patients with XDR-TB and home-discharged patients with programmatically incurable TB

by Ruth MCNERNEY

To share a new publication (attached) Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study Lancet Respir Med 2017 Dheda et al Background: The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. The aim of ... read more

Updated: 19 Jan, 2017
Replies: 0

Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial

Erica Lessem replied

Thank you, Masoud, for sharing this important study. This was a very nice paper, and good to see the impact of using Xpert in active case finding not only on increasing the proportion of patients starting treatment, but also in reducing the time to treatment initiation from 4 days to ... read more

Updated: 17 Jan, 2017
Recommendations: 2
Replies: 5

Empircal treatment of MDR TB in a previous treated patient, yes or not?

Beatriz Alonso replied

Dear all. Thanks for your replys. For the first tuberculosis, I donĀ“t know her adherence, but for the second one (this that has finished in failure) it has been good. she has just missed 5 doses in intensive phase and they prolonged until 3 months this phase. Even without DOT, ... read more

Updated: 11 Jan, 2017
Recommendation: 1
Replies: 9

New community members

User Photo

Alexandra Todd

Affiliated Organizations

International Panel Physicians Association

Work Locations

United States

User Photo

Rajendra Karnatak

Affiliated Organizations

HEALTH

Work Locations

United States

User Photo

DALIA SECIN

Affiliated Organizations

Palm Beach State College

Work Locations

United States